Kynos Therapeutics

About:

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Website: https://www.kynostx.com/

Twitter/X: KynosTxLtd

Top Investors: Innovate UK, IP Group, Scottish Enterprise, Epidarex Capital

Description:

Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.

Total Funding Amount:

9M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Edinburgh, Edinburgh, City of, United Kingdom

Founded Date:

2020-01-01

Contact Email:

admin(AT)kynostx.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2022-04-07

IPO Status:

Private

Industries: